{"entity":{"id":"nct07214779","kind":"trial","name":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","aka":["MAESTRA 2"],"tldr":"A phase 3 trial testing INCB123667 in ovarian cancer, now recruiting.","summary":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression is a phase 3 interventional study registered as NCT07214779, led by Incyte with ENGOT Foundation and GOG Foundation, and recruiting on the registry. Official title: A Phase 3, Randomised, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression. Planned enrolment is 466 participants (estimated). The study started in 2025-12-09 and primary completion is expected in 2028-11-15. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07214779","url":"https://clinicaltrials.gov/study/NCT07214779"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian","platinum-resistant-ovarian-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["incb123667"],"companies":["incyte"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07214779","phase":"3","setting":"A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","sponsor":"Incyte","participation":[{"nct":"NCT07214779","source":"https://clinicaltrials.gov/study/NCT07214779","fetchedAt":"2026-10-07T16:55:33.599Z","studySha256":"b655fd3a34f7ffb0628161440f4c60e5f46eff1775c2264c5a2c17e69d647253","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-15","leadSponsor":"Incyte Corporation","collaboratorCount":2,"minimumAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":466,"enrolmentType":"ESTIMATED","siteCount":192,"recruitingSiteCount":43,"countries":["Australia","Belgium","Canada","France","Germany","Ireland","Italy","Japan","Netherlands","Poland","Puerto Rico","South Korea","Spain","Switzerland","United Kingdom","United States"]}],"started":"2025-12-09","startedType":"actual","enrolled":466,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07214779/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"drug":[{"id":"incb123667","kind":"drug","name":"INCB123667","route":"/drugs/incb123667/"}],"company":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"}]}}